EUVIMEDEUVIMED entdecken
Crossref

Isoquinolinequinone N-oxides as potent antitumor compounds against pancreatic cancer cell lines: preliminary results

Rodrigues, Rúben, Ryan D. Kruschel, Florence O. McCarthy, Vasconcelos, M. Helena, P. R. Xavier, Cristina

Science Letters · 03.05.2025

DOI: 10.48797/sl.2025.303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Letters, erschienen am 03.05.2025. Verfasst von Rodrigues und 7 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies, being the 7th leading cause of cancer-related mortality worldwide. PDAC remains associated with an extremely poor prognosis, owing to drug resistance and to the lack of alternative therapeutic options. Standard chemotherapy typically involves gemcitabine, either alone or combined with paclitaxel. Moreover, Chitinase-3-Like 1 (CHI3L1) was identified as a key protein responsible for reducing PDAC drug response in vitro [1]. Thus, the identification of new molecules with antitumor potential and that can counteract drug resistance will be of great significance, as new therapeutic agents to be used either alone or in combination with chemotherapy. Interestingly, a family of Isoquinolinequinone (IQQ) N-oxides with antitumoral activity against counterpart pairs of sensitive and multidrug-resistant cell lines from non-small cell lung cancer and colorectal cancer has been recently identified [2,3].

Objective

The aim of this study is to explore the antitumor and chemosensitizing activity of a family of seven IQQ N-oxides in a panel of PDAC cell lines.

Methods

The cytotoxicity effect of seven IQQ N-oxides is being assessed with the Sulforhodamine B (SRB) assay in four PDAC cell lines: PANC-1, BxPC3, Miapaca-2 and Capan-2. Gemcitabine was used as a positive control [1]. The impact of these compounds on the expression levels of CHI3L1, β-catenin and other proteins involved in relevant cancer-related pathways, such as ERK signalling, will be analysed by Western blotting. Furthermore, the therapeutic combination of the most promising IQQ N-oxides with gemcitabine will be evaluated by SRB.

Results

Preliminary results demonstrated that the GI50 concentrations of three IQQ N-oxides were around or below 2 µM, in both PANC-1 and BxPC3 cell lines.

Conclusion

This preliminary work highlights the antitumor potential of these isoquinolinequinone N-oxides in PDAC cell lines.

Schlagwörter

pancreatic ductal adenocarcinomaanticancer activitychemosensitizationYKL-40multidrug resistancegemcitabineβ-cateninERK signalingpancreatic cancer cell linesPANC-1 cells

Zitieren

APA

Rodrigues, Rúben, Kruschel, R. D., McCarthy, F. O., Vasconcelos, Helena, M., Xavier, P. R., & Cristina (2025). Isoquinolinequinone N-oxides as potent antitumor compounds against pancreatic cancer cell lines: preliminary results. Science Letters. https://doi.org/10.48797/sl.2025.303

Vancouver

Rodrigues, Rúben, Kruschel RD, McCarthy FO, Vasconcelos, Helena M, et al. Isoquinolinequinone N-oxides as potent antitumor compounds against pancreatic cancer cell lines: preliminary results. Science Letters. 2025. doi:10.48797/sl.2025.303

BibTeX
@article{Rodrigues2025,
  author = {Rodrigues and Rúben and Kruschel, Ryan D. and McCarthy, Florence O. and Vasconcelos and Helena, M. and Xavier, P. R. and Cristina},
  title = {Isoquinolinequinone N-oxides as potent antitumor compounds against pancreatic cancer cell lines: preliminary results},
  journal = {Science Letters},
  year = {2025},
  doi = {10.48797/sl.2025.303}
}
Kostenlos starten →